StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Closing Consideration is coming up

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Jul 22, 2021 4:46am

156 Views

Post# 33586481

RE:Closing Consideration is coming up

Say, when the LOI states that Care will get the extra 8Million shares "contingent
upon the achievement of certain performance milestones"... Does that mean we're going to see some Aristotle revenues in the next financials?
I'm thinking that that's exactly what it means!
And now that we've added rapid antigen testing, just. in. time. for. the. interntational. travel. BOOM!
Move over, ScroogeMcDuck! It's my turn to take a dive in the money vault! hahahaha
GLTA!!

Nailbiter1 wrote: C'mon Jimmy T.
Put some pepper on it.

The letter of intent commits the HC Companies to negotiate exclusively with StageZero for one hundred and twenty (120) days, and is binding as to payment terms. The payment terms contemplate that StageZero will issue 15,000,000 common shares (the "Closing Consideration") to the vendors on the closing of the Transaction, with an additional 8,000,0000 common shares (the "Contingent Consideration") potentially issuable to the vendors post-closing, contingent upon the achievement of certain performance milestones.